Business Description
GNI Group Ltd
ISIN : JP3386370005
Total Employee Number:
1,040Description
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases. The company's business activities are divided into the pharmaceutical business and the medical device business. In the pharmaceutical business, the company conducts research and development, manufacturing, and sales of development compounds, mainly I-Suru, which is sold in the Chinese market, and F351, which has completed clinical trials. In the medical device business, the company develops, manufacture, and sell medical devices (biomaterials) based in the United States.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.02 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | -1.32 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 3.8 | |||||
Beneish M-Score | -2.5 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.1 | |||||
3-Year FCF Growth Rate | -32.8 | |||||
3-Year Book Growth Rate | 26.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 29.58 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 36.49 | |||||
9-Day RSI | 43.43 | |||||
14-Day RSI | 45.42 | |||||
3-1 Month Momentum % | -14.29 | |||||
6-1 Month Momentum % | 9.92 | |||||
12-1 Month Momentum % | -18.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.08 | |||||
Quick Ratio | 3.63 | |||||
Cash Ratio | 2.84 | |||||
Days Inventory | 183.97 | |||||
Days Sales Outstanding | 85.19 | |||||
Days Payable | 86.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.4 | |||||
Shareholder Yield % | -6.45 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 73.58 | |||||
Operating Margin % | -20.14 | |||||
Net Margin % | -21.6 | |||||
EBITDA Margin % | -14.45 | |||||
FCF Margin % | -16.98 | |||||
OCF Margin % | -9.21 | |||||
ROE % | -13.3 | |||||
ROA % | -7.59 | |||||
ROIC % | -11.05 | |||||
ROC (Joel Greenblatt) % | -46.76 | |||||
ROCE % | -7.61 | |||||
Years of Profitability over Past 10-Year | 6 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 55.81 | |||||
Shiller PE Ratio | 202.86 | |||||
PS Ratio | 5.03 | |||||
PB Ratio | 2.9 | |||||
Price-to-Tangible-Book | 7.34 | |||||
EV-to-EBIT | -29.78 | |||||
EV-to-EBITDA | -38.66 | |||||
EV-to-Revenue | 5.59 | |||||
EV-to-FCF | -32.47 | |||||
Price-to-GF-Value | 0.94 | |||||
Price-to-Projected-FCF | 5.72 | |||||
Price-to-Median-PS-Value | 0.66 | |||||
| Price-to-Net-Current-Asset-Value | 30.36 | |||||
Earnings Yield (Greenblatt) % | -3.36 | |||||
FCF Yield % | -2.71 | |||||
Forward Rate of Return (Yacktman) % | -8.34 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GNI Group Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 153.643 | ||
| EPS (TTM) (€) | -0.595 | ||
| Beta | 0.1582 | ||
| 3-Year Sharpe Ratio | 0.54 | ||
| 3-Year Sortino Ratio | 1.25 | ||
| Volatility % | 40.49 | ||
| 14-Day RSI | 45.42 | ||
| 14-Day ATR (€) | 0.434649 | ||
| 20-Day SMA (€) | 13.905 | ||
| 12-1 Month Momentum % | -18.18 | ||
| 52-Week Range (€) | 11.9 - 19.6 | ||
| Shares Outstanding (Mil) | 65.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GNI Group Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GNI Group Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| 3:1 Stock Split | 2019-09-02 | 15.18 (+0.00%) | ||
| 0.1:1 Stock Split | 2018-06-27 | 12.03 (+0.00%) |
Show
Entries
GNI Group Ltd Frequently Asked Questions
What is GNI Group Ltd(FRA:3G6)'s stock price today?
The current price of FRA:3G6 is €13.70. The 52 week high of FRA:3G6 is €19.60 and 52 week low is €11.90.
When is next earnings date of GNI Group Ltd(FRA:3G6)?
The next earnings date of GNI Group Ltd(FRA:3G6) is .
Does GNI Group Ltd(FRA:3G6) pay dividends? If so, how much?
GNI Group Ltd(FRA:3G6) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on GNI Group Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers